outlook outlook g hostwriting is when someone sub stantially contributes to a manu script, but is not mentioned in the byline or in the acknowledgements. at its extreme, ghostwriting is used by companies that pay professional writers to produce an article that supports the product of that com pany, while authorship is attributed to aca demic scientists. this practice conceals the involvement of the company and can affect perception of the effectiveness and safety of a product. pharmaceutical and commu nication companies in particular have con structed a vast and profitable ghostwriting industry. in 2001, an estimated 100 or more communications companies advertised their services for supplying and improving manuscripts (Barbour, 2010; landow, 2002) . ghostwriting in biomedical research carries a substantial risk for public health. ghostwritten articles might influence physi cians to prescribe more expensive treat ments that are less effective, or even risky (Singer & Wilson, 2009 ). Moreover, uS and European medical professors are reported to have been included as guest authors of ghostwritten papers-some of them even listing these papers on their curriculum vitae-which suggests that promotions or grants could be awarded on the basis of false authorship (lacasse & leo, 2010) . i t is difficult to determine the extent of ghostwriting owing to both secrecy and a lack of research. Flanagin et al (1998) found that of 809 articles published in peerreviewed medical journals, for 156 (19%) there was evidence that guest authors had not substantially contributed to the article, 93 (11%) included ghost authors, and for 13 articles (2%) there was evidence of both. Highly publicized con cerns about ghostwriting first appeared over the fenfluramine /phentermine diet drugs, which were withdrawn in 1997 owing to safety concerns, and rofecoxib, which was withdrawn in 2004 (Singer & Wilson, 2009) . in 2008, during rofecoxibrelated li tigation, court documents obtained from the pharma ceutical company Merck revealed that un acknowledged authors had writ ten clinical trial and review manuscripts, and first authorship was often attributed to academic investigators who were offered fees and did not always declare financial support received from industry (ross et al, 2008) . in 16 of the 20 clinicaltrial reports analysed, Merck employees were listed as authors on manuscript drafts, but the pub lished study listed an academic as the lead author. Merck also hired companies to write 72 review articles, 50 of which listed only academic scientists as authors.
gøtzsche et al (2007) analysed reports of industryinitiated clinical trials that were approved between 1994 and 1995 by Danish ethics committees. they found evi dence of ghostwriting in 31 of 44 cases. Documents released by a uS federal court in 2009 showed that the pharmaceutical company Wyeth had paid a medical writing company to draft articles as part of a well planned campaign to support its meno pausal hormone therapy products. these articles used ghostwriters and guest authors, despite increasing evidence that some of the drugs increased the risk of breast cancer (Barbour, 2010; Singer & Wilson, 2009; ploS Medicine Editors, 2009) . PLoS Medicine revealed that Wyeth used ghostwritten articles to down play the associated risks of breast cancer, support unproven cardiovascular 'benefits', and encourage unverified, offlabel use such as for prevention of parkinson disease and dementia (FughBerman, 2010) . So far, research and lawsuits have shown that drug companies have used ghostwriting to mar ket at least 10 drugs (lacasse & leo, 2010) . the issue of ghostwriting is likely to impinge on other areas in the life sciences in which substantial economic interests are at stake, such as plant and agricultural research and bio technology companies. i n fact, ghostwriting is a common pheno menon. Many politicians and celebrities use ghostwriters to write or edit speeches, write opinion articles for news papers and even their own memoirs. However, ghost writing in the medical literature poses a risk because it could influence opinion about drugs and treatments both in academic cir cles and among politicians. a recent story in the New York Times illustrates the influ ence pharmaceutical companies wield over uS congress; during the healthcare debate, 22 republicans and 20 Democrats cited probiotechnology articles that were ghost written by lobbyists working for genentech. genentech, in fact, produced separate posi tion papers in support of the healthcare reform bill and provisions designed to be (gøtzsche et al, 2009) ? there are also instances of professional writers merely providing a first draft of a paper for the sake of expediency; a busy academic might not have to write the article from scratch. in these instances, the intellec tual effort predominantly comes from the academic, and the writer simply provides editorial support. Should this kind of contri bution from medicalwriting companies be considered as ghostwriting? ghostwriting often occurs in tandem with guest authorship-also called honor ary authorship-which is the naming of authors whose contributions are so mea gre that they do not deserve a place on the byline (gøtzsche et al, 2009) . there are similar problems with genetic studies writ ten on the basis of large data sets. When author X has ethical permission to study a set of patients whose Dna is included in a much larger study done by author y, both X and y eventually put their names on the paper. although the work respects the origi nal ethical stipulations, y does not have a right to use these samples, other than within a collaborative study.
…in my opinion, ghostwriting violates the integrity and ethical principles of scientific research
science & society outlook the question is whether a person whose only input is to supply samples for a study should be included as an author. although some traditional researchers disapprove of this practice, there is often no way of publish ing studies based on thousands of samples without including all who have participated in some way. More generally, large sequenc ing projects and genomewide association studies have created an authorship problem; long lists of authors make it almost impossi ble to determine who has contributed what. For example, many studies by the Wellcome trust casecontrol consortium include as authors all researchers who have included material for the controls, even if they have contributed nothing else.
Following the most rigorous criteria for authorship-for instance those by the international committee of Medical Journal Editors (icMJE)-and recognizing that nobody likes being mentioned only in the acknowledgements, i propose that author ship should be determined on the basis of criteria indicative of both personal effort and accountability. acquisition of funding, collection of data or general supervision of the research group alone do not constitute authorship (icMJE, 2008) . colleagues who have only provided samples should receive an acknowledgement to avoid possible charges of unethical guest authorship. S ome argue that ghostwriting is a form of plagiarism, as it attributes authorship for the work to others, although the apparent 'victim'-the company-is basic ally inviting the scientist to 'steal' its work and publish it as their own (Krimsky, 2007; anekwe, 2010) . However, the ghost is not plagiarizing anyone, and guest authors are not plagiarizing the ghost. it might also be argued that there are circumstances in which different authorship contributions make little difference to the outcome. What, then, about the argument that ghostwriting makes no dif ference, and that weeding it out is a waste of time and limited resources? after all, it is the data and analysis that matters, not the name on the top of the article. However, in my opinion, ghostwriting violates the integrity and ethical principles of scientific research.
Some countries and organizations have recognized and begun to tackle the prob lem of ghostwriting and guest authorship. Danish law, for instance, regards mis appropriation of authorship as research misconduct (Danish Ministry of Science, technology and innovation, 2005). in regard to ghostwriting, the law on scientific dishonesty, which came into force in 2009, includes the definition of dishonesty as "false credit given to the author or authors, misrepresentation of title or workplace". in 2009, the institute of Medicine recom mended that uS academic medical cen tres enact comprehensive policies to ban ghostwriting, a process often referred to as 'ghostbusting ' (Singer & Wilson, 2009; Fugh Berman, 2010) , to prohibit "educational presentations or scientific publications that are controlled by industry or that contain substantial portions written by someone who is not identified as an author or who is not properly acknowledged" (institute of Medicine, 2009).
Journals and editors' associations also increasingly require author contribution and competing interest statements to name all those involved in writing an article (table 1) . in 2005, the World association of Medical Editors (WaME) developed specific policies on ghostwriting, calling it dis honest and sanctionable (WaME, 2005) .
lacasse & leo (2010) found that 10 of the top50ranked medical research cen tres in the uSa explicitly prohibit ghost writing, seven included some definition of ghostwriting in their policy and three pro hibited ghostwriting without defining the term. However, 13 did not ban all aspects of ghostwriting, most notably by not requiring that all qualified authors are listed.
Some websites, such as that of Wash ington university in St louis, uSa, con tain explicit warnings on ghost and honorary authorship, emphasizing that even in correctly acknowledging contri butions to published research violates its authorship policies, and might be referred to the research integrity officer as research mis conduct (www.wustl.edu/policies/ authorship). a 2009 survey of 10 leading medical schools in the uSa found that six schools explicitly forbid ghostwriting. Some schools, such as Washington university, have also adopted the recommendations of the icMJE. W hether professional medi cal writers qualify as authors remains debatable (gøtzsche et al, 2009; Wager, 2007; Jacobs & Wager, 2005) . the Danish committees on Scientific Dishonesty state that although professional writers seldom meet icMJE criteria-as they are not involved in study design, data gather ing or interpretation-their contribu tion must be acknowledged as a potential conflict of interest (the Danish committees on Scientific Dishonesty, 2003) . the European Medical Writers association states that professional writers are usually not eli gible for authorship, although their role should be acknowledged (Jacobs & Wager, 2005) . conversely, peter gøtzsche, Director of the nordic cochrane centre, suggests that editors should insist that medical writ ers be authors, because it is inconceivable …it is surprising that funding agencies have not enacted policies to avoid ghostwriting Despite these efforts, a JAMA study of 630 research, review and editorial/opinion articles from six top medical journals in 2008, found that onequarter of articles had honorary authors, 8% had ghost authors and 2% had both, and that these numbers had changed little since 1996 (Wislar et al, 2009) . responses in industry have included the adoption of icMJE authorship guidelines by the pharmaceutical research and Manu facturers of america (2009), who suggested that these should be applied industrywide and state the effect of the sponsor on the study design, data collection and writ ing. Similarly, the association of the British pharmaceutical industry does not support ghostwriting practices (http://www.abpi. org.uk/mediacentre/newsreleases/2005/ pages/130405.aspx). the industryrun inter national publication planning association (tippa) has taken a more active role, by encouraging good publication practices throughout the industry. g iven these efforts, it is surprising that funding agencies have not enacted policies to avoid ghostwriting. regrettably, the national institutes of Health (niH) in particular, given its importance for medical research, is missing this oppor tunity. the uS public Health Service, of which the niH is a part, is the only federal agency with specific regulations regarding the statement of financial conflicts of interest (Fcoi) in research and, to my knowledge, no pub lic funders in other countries have specific rules on Fcoi or ghostwriting. although the niH cannot direct policies for all research in the uSa, it could address the issue in its disclosure policies, which would act as a benchmark for other agencies.
the revised niH regulations would move the responsibility for determining whether the financial interests of investigators are related to niHsupported research from investigators to institutions, and would also lower disclosure thresholds from ten to five thousand dollars (rockey & collins, 2010) . However, explicit policies on the disclosure of industryfinanced ghostwritten articles are not being contemplated. this seems to conflict with niH director Francis collins' recent comment that "people would allow their names to be used on articles they did not write, that were written for them, par ticularly by companies that have something to gain by the way the data is presented […] if we want to have the integrity of sci ence preserved, that's not the way to do it" (cSpan, 2009) . recent disclosures by the project on government oversight (pogo), an inde pendent, nonprofit organization, show that the niH has provided millions of dol lars to medical investigators who employ ghostwriters funded by pharmaceutical companies. one example involved two academics supported by the niH who were listed as authors of a physicians' handbook, part of which were written by Scientific therapeutics information, a marketing com pany employed by glaxoSmithKline (gSK) to support paxil (paroxetine), an anti depressant. the published handbook rec ognized "editorial assistance" from the marketing company and an "unrestricted educational grant" from gSK (http:// pogoblog.typepad.com/pogo/2010/12/ ghostbustersatpogo.html).
in December 2010, pogo sent a letter to collins urging him to ban ghostwriting in niHbased academic centres, in order to strengthen scientific integrity (http://www. pogo.org/pogofiles/letters/publichealth/ phiis20101129.html). collins replied that "[although] the niH extramural policy governing niH grantees does not use the term ghostwriting, Federal regulations and W aME, copE, the institute of Medicine and some journal edi tors and independent authors recommend specific policies to regu late ghostwriting (table 2; titus & Bosch, 2010) . However, only enforceable poli cies are useful. this requires an unambigu ous definition of ghostwriting. in addition, journals-not only in clinical medi cine, but also in other life sciences-should not accept meaningless acknowledgement of nonspecific editorial or technical assist ance. institutions that lack policies on authorship and ghost writing should adopt existing models, such as that of Washington university. ideally, such policies should emphasize the requirement for full trans parency about the role of pharma ceutical and other firms in the genesis of the article.
governments, in turn, should not support institutions that allow ghostwriting by omis sion and which have no specific authorship policies. research funders should sup port greater transparency, disclosure and responsibility by making grant decisions contingent on adherence to authorship guidelines that explicitly ban ghost writing. the uK Medical research council sub scribes to icMJE guidance on appropriate authorship but ignores ghostwriting; so does the Wellcome trust, whose statement that "honorary authorship is unacceptable" is not enough. Supranational funders, not ably the European commission (Ec), through its Framework research programmes, and the European Science Foundation (ESF), should do similarly. the ESF has recently published a European code of conduct for research integrity (ESF, 2010; Bosch, 2010) which, although calling ghost authorship un acceptable, goes no further. Both the Ec and the ESF are wellpositioned to appoint independent experts to investigate ghost writing allegations. initially, the Ec could request its advisory European group on Ethics to generate recommendations. S imilarly, national bodies such as the uK Department of Health-which sets out good practice in the conduct of clinical trials to define the roles and responsi bilities of investigators and trial sponsors-ignore authorship and ghost writing. these bodies should include explicit statements on author ship in goodpractice guidelines, and indicate that ghostwriting will be prosecuted.
the niH could lead the discussion and guarantee that its grant recipients adhere to a higher level of transparency and accounta bility. this could be achieved by requiring all niHfunded institutions to explicitly recog nize, make public and enforce a prohibition of ghostwriting, by rules or amendments to the report. in particular, the Management and reporting of Fcoi section of the niH proposed rule report (HHS, 2010) should include such stipulations. in addition, as suggested by uS Senator charles grassley, the new niH Fcoi regulations should consider requiring that articles based on niHfunded research are only published in journals that enforce ghost writing poli cies (grassley, 2010) . other health agen cies using taxpayer money, such as the FDa, should do the same. the uK research integrity office, as part of the wider European network of research integrity offices, should define ghost writing and class it as research misconduct. Similarly, the uK general Medical council and equivalent bodies should formulate explicit guidance on what constitutes honest authorship. as ghostwriting might affect areas other than clinical medicine, journals, institutions and organizations that specialize in basic research in the life sci ences and translational medicine should join efforts to prevent and monitor the practice.
Moreover, bodies such as the uS office of research integrity should create and enforce regulatory policies on ghost writing and consider it as research misconduct, following the Danish lead. in view of the importance of authorship to career progres sion, i would further argue that all trans gressions of authorship, such as changing, omitting or adding names to bylines and misappropriation of authorship in general, are also research misconduct. g iven the amount of litigation involv ing the drug industry in recent years, it is surprising that no company has been sued for ghost writing, as highvisibility lawsuits could rapidly terminate the prac tice. in the uSa, lawyers could contend that ghostwriting violates the False claims act (Fca) and companies submitting a new drug application to the FDa in slanted, ghostauthored studies are likely to state a risk-benefit estimate that is not supported by evidence. in addition, products determined to be unsafe and in effective for any indica tion do not qualify for Medicare or Medicaid reimbursement, and any federal money spent might have been falsely obtained according to the Fca (Morrissey, 2010) .
Finally, to better protect public health, industry insiders with knowledge of ghost writing should be urged to come forward. Whistleblowers should be aware that they can be rewarded under successful lawsuits brought by the Fca. However, additional protection would be needed to protect whistleblowers, using strategies to help them remain anonymous. in the current cli mate, prevention is preferable to and more feasible than punishment. Selfregulation, especially by commercially interested par ties is unlikely to be effective, but rigorous public policies could successfully regulate this problem.
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